OTIC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTIC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), Otonomy's share price is $0.0085. Otonomy's Tangible Book per Share of Sep. 2022 for the quarter that ended in Sep. 2022 was $0.38. Hence, Otonomy's Price to Tangible Book Ratio of today is 0.02.
The historical rank and industry rank for Otonomy's Price-to-Tangible-Book or its related term are showing as below:
A closely related ratio is called PB Ratio. As of today, Otonomy's share price is $0.0085. Otonomy's Book Value per Sharefor the quarter that ended in Sep. 2022 was $0.38. Hence, Otonomy's P/B Ratio of today is 0.02.
The historical data trend for Otonomy's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otonomy Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.45 | 0.71 | 2.93 | 4.72 | 2.15 |
Otonomy Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.64 | 2.15 | 3.16 | 3.69 | 0.79 |
For the Biotechnology subindustry, Otonomy's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Otonomy's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Otonomy's Price-to-Tangible-Book falls into.
Otonomy's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2022 ) |
= | 0.0085 | / | 0.375 | |
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Otonomy's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Hogan H Michael Iii | director | C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355 |
Vickie L Capps | director | 2985 SCOTT STREET, VISTA CA 92083 |
Alan Charles Foster | officer: Chief Scientific Officer | 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121 |
Savel Robert Michael Ii | officer: Chief Technical Officer | 1025 OPAL WAY, VACAVILLE CA 95687 |
Paul E Cayer | officer: CFO/Ch. Business Offcr & Sec. | C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
David Allen Weber | director, officer: President & CEO | C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
Jill Marie Broadfoot | director | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Jay Lichter | director | C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211 |
Ciara Kennedy | director | C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130 |
James B Breitmeyer | director | |
Eric J Loumeau | officer: GC & Chief Compliance Officer | C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
Katherine Mary Bishop | officer: Chief Scientific Officer | C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121 |
Carl Lebel | officer: Chief Scientific Officer | 23256 MARIPOSA DE ORO, MALIBU CA 90265 |
Iain Mcgill | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Chau Quang Khuong | director | C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-11-2022
By GuruFocusNews GuruFocusNews • 06-17-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 05-19-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 06-07-2022
By Tiesvg Tiesvg • 12-22-2022
By PRNewswire PRNewswire • 11-29-2022
By GuruFocusNews GuruFocusNews • 05-02-2022
By Value_Insider Value_Insider • 11-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.